95 results about "Host disease" patented technology

The purpose of the present invention is to provide: a novel therapeutic or prophylactic agent for xerophthalmia; a therapeutic or prophylactic agent for graft-versus-host disease; a corneal epithelium wound healing promoter; a corneal invasive inflammatory cell inhibitor; or an inhibitor of differentiation of lymphocytes into effector T cells. The present invention provides: a therapeutic or prophylactic agent for xerophthalmia, a therapeutic or prophylactic agent for graft-versus-host disease, a corneal epithelial wound healing promoter, a corneal invasive inflammatory cell inhibitor, a tear amount maintenance agent, a corneal epithelial damage inhibitor, and a method for preparing the same, which comprises, as an active ingredient, a substance derived from a stem cell culture supernatant; a cell proliferation marker positive cell inhibitor, or an inhibitor of differentiation of lymphocytes to effector T cells.

The invention provides sgRNA for targeting and guiding nuclease to efficiently cut an HLA-DRA gene, a method for modifying a CAR-T cell by using the sgRNA, and a related gene editing system, reagent and kit. According to the CAR-T cell, the immunogenicity is greatly reduced, the risk of graft versus host disease and immunological rejection can be effectively reduced, and meanwhile the killing capacity of tumor cells of the CAR-T cell is not affected.

The present invention relates to high density lipoprotein (HDL) or HDL mimetics for use in the prevention and / or treatment of graft-versus-host disease (GvHD) or cytokine release syndrome in a subject.

This invention provides an antibody composition with improved stability, exhibiting reduced fragmentation of the antibody polypeptide chain during manufacturing and subsequent storage. [Solution] This disclosure relates to improved compositions and methods for treating T cell-mediated diseases and disorders (e.g., autoimmune disorders, graft-versus-host diseases, and graft rejection). Provided are antibody-containing anti-αβTCR binding polypeptides comprising at least one amino acid substitution or modification that enhances the stability of the binding polypeptide by reducing fragmentation of the light chain variable region. Methods provided herein generally involve administering an effective amount of a stabilized, humanized binding polypeptide specific to the alpha-beta T cell receptor (αβTCR) to a subject in need thereof.

This disclosure relates to an immunoglobulin single variable domain (ISVD)-containing modulator that allosterically binds to a three-dimensional (3D) epitope of a protein complex comprising at least one inhibitory immune receptor and at least one corresponding ligand. The modulator regulates cooperativity within such complexes, thereby affecting the binding affinity and downstream signaling pathways. Specifically, the allosteric modulator of this invention induces positive cooperativity in immunoinhibitory receptor-ligand complexes, thus suppressing immune responses in a spatiotemporally restricted manner. Accordingly, these allosteric modulators are useful as therapeutic agents for inflammatory diseases, such as autoimmune diseases, allergic diseases, or graft-versus-host disease (GVHD). Moreover, this disclosure pertains to methods for identifying, selecting, and producing said allosteric modulators.

The present invention provides a method of reducing the likelihood of a subject having graft versus host disease or a method of treating graft versus host disease in a subject comprising analyzing a gastrointestinal biopsy of the subject to measure the number and density proportion of cells and administering to the subject a pharmaceutically effective amount of one or more immunosuppressive agents.

The present invention provides a liposome preparation containing a population of liposomes containing a CD1d ligand compound, wherein the average particle size of the population of liposomes is 90 to 110 nm and the polydispersity index of particle size distribution is 0.2 or less. and the polydispersity index of the particle size distribution is 0.2 or less. The present invention also provides the use of the liposome preparation in the prevention or treatment of graft-versus-host disease and organ transplant rejection.

The application discloses a method for establishing a mouse model of MHC haplotype compatible allogeneic hematopoietic cell transplantation, and belongs to the technical field of animal experiment model construction. The technical problem to be solved by the application is how to construct a mouse model which can be used to study the immune reconstruction mechanism and treatment effect evaluation of MHC haplotype compatibility and MHC full compatibility in bone marrow cell transplantation recipient mice. To solve the technical problem, the application provides a method for constructing a mouse model of MHC haplotype compatible allogeneic hematopoietic cell transplantation, which comprises transplanting bone marrow cells of a donor mouse into a recipient mouse, and the MHC haplotype of the donor mouse and the recipient mouse is compatible. The application sets a modeling condition, and the model establishment condition is evaluated by survival condition, graft-versus-host disease and rejection reaction observation, flow cytometry and histopathological section, so as to prove that the model is reliable and stable.

The present invention provides a novel use and methods comprising antibodies, or antigen-binding fragments thereof, which bind to a CCR7 receptor for use as a novel therapeutic agent in prevention and / or treatment of graft versus host disease (GVHD), preferably in hematopoietic stem cell transplantation (HSCT), more preferably allogeneic hematopoietic stem cell transplantation. GVHD of the invention can be acute (aGVHD) and / or chronic (cGVHD), preferably acute. The antibodies and antigen-binding fragments are capable of selectively depleting ex vivo or in vitro immune cells expressing CCR7 and are capable in vivo of selectively killing immune cells expressing a CCR7 receptor and of impairing / blocking migration and of activation of said immune cells, which are involved in the development and evolution of GVHD. The use of said antibodies for depleting, killing and impairing / blocking migration and activation of immune cells expressing CCR7 cells is disclosed, thus providing an alternative therapy for preventing and treating GVHD in both acute and chronic types.

This invention relates to double-stranded oligonucleotides complementary to JAK1 that result in the regulation of JAK1 expression. Regulation of JAK1 expression is beneficial for a range of medical disorders, including inflammatory bowel disease, organ transplant rejection, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis (RA), juvenile idiopathic arthritis, psoriasis, dermatitis, diabetic nephropathy, systemic lupus erythematosus (SLE), dry eye disease, cancer, myelofibrosis, and asthma. The invention also includes compositions comprising double-stranded oligonucleotides and therapeutic methods using double-stranded oligonucleotides.

The present invention relates to a compound of Formula (I), in particular, the compound of Formula (II) or an isotopic variant, a pharmaceutically acceptable salt or solvate thereof for use in a method of treatment of graft-versus-host disease in a subject in need thereof.

The present application belongs to the field of photochemical therapy, and particularly relates to a method for photochemical treatment of riboflavin based on multi-wavelength LED and application thereof in treatment of graft-versus-host disease. The present application selects different wavelength LED combinations as light sources to optimize the riboflavin photochemical method, controls the light intensity at 1000-25000 μW / cm², controls the irradiation time at 5-15 minutes, and controls the riboflavin concentration at 20-150 μM, thereby significantly improving the photochemical reaction effect. The method can efficiently induce PBMC apoptosis in a plasma environment, significantly reduces the levels of key pro-inflammatory cytokines such as TNF-α, IL-6 and IFN-γ, and has no significant influence on platelets, hemoglobin and blood clotting function, thereby providing a safe and controllable new cell preparation method for GVHD treatment.

A method for treating subjects with graft-versus-host disease (GvHD) or at risk of developing GvHD, using CD90 with stronger immunomodulatory capabilities. + hAEC cell populations were used as the primary therapeutic cells. Studies on the related mechanism of action revealed that CD90... + hAECs showed significantly higher levels of stem cell pluripotency markers SSEA4, OCT4, and NANOG than typical hAECs, and also exhibited better immunomodulatory functions; therefore, CD90 was used as a marker. + hAECs cells can be used as a treatment to achieve better clinical outcomes.

To provide a novel cell therapeutic agent that can improve GVHD treatment efficacy by strengthening immunomodulatory activity of MSC through use of a TLR5 agonist.SOLUTION: The present invention relates to a pharmaceutical composition for prevention or treatment of graft-versus-host disease, the composition containing, as an active ingredient, mesenchymal stem cells treated with a TLR5 (Toll-like receptor 5) agonist. The composition of the present invention is excellent in ability to reduce variability under a low-grade inflammatory environment and to exert an immunomodulatory effect, and can be utilized as an MSC-based therapeutic agent for steroid-resistant graft-versus-host disease (GVHD).SELECTED DRAWING: Figure 5b

The invention belongs to the technical field of medicines, and particularly relates to a 4, 5, 6, 7-tetrahydropyrazolo [1, 5-a] pyrazine derivative and application thereof. The derivative disclosed by the invention is a compound shown in a general formula (I) and pharmaceutically acceptable salts thereof, and A, L and Q are described in the specification. The compound disclosed by the invention has relatively strong ROCK2 inhibitory activity in vitro, and can be used for treating ROCK2 related diseases, such as chronic graft versus host disease, tumor or fibrosis and the like.

The present disclosure relates to extracellular vesicles (EVs), e.g., exosomes, comprising a payload (e.g., an antigen, adjuvant, and / or immune modulator) and / or a targeting moiety. Also provided herein are methods for producing the EVs (e.g., exosomes) and methods for using the EVs (e.g., exosomes) to treat and / or prevent diseases or disorders, e.g., cancer, graft-versus-host disease (GvHD), autoimmune disease, infectious diseases, or fibrotic diseases.

This invention relates to the selective removal of activated T cells using a monovalent antibody or its antigen-binding fragment, which includes heavy chain variable regions and light chain variable regions of an antibody that specifically binds to CD3. In one embodiment of the present invention, the monovalent anti-CD3 antibody or its antigen-binding fragment is useful as a T cell removal agent or T cell immunosuppressant because it can selectively remove only activated T cells without affecting non-activated T cells. In particular, this invention is useful for the prevention or treatment of T cell-mediated autoimmune diseases, graft-versus-host diseases, or organ transplant rejection, as well as for the prevention of graft-versus-host disease (GVHD) side effects in allogeneic CAR-T cell therapy.

To provide compositions comprising components of multi-component CALs or CARs, and to provide methods for treating autoimmune diseases and the like.SOLUTION: A composition is provided comprising a TCR recognition domain and one or both of (a) an intracellular signaling domain and (b) a first-type protein interaction domain. Further provided is a method for treating or preventing autoimmune disease, transplant rejection, or graft-versus-host disease.SELECTED DRAWING: Figure 10

The anti-CD40L / anti-CD28 bispecific antibody according to the present application comprises anti-CD40L scFv and anti-CD28 scFv, and thus does not exhibit a thromboembolic side effect, can exhibit an excellent effect of treating autoimmune diseases and / or graft versus host diseases while preventing a T cell activation effect caused by CD28 dimer formation, and can be used as a novel anti-CD40L / anti-CD28 bispecific antibody. In addition, excellent bispecific antibody physical characteristics can be shown.

This disclosure relates to extracellular vesicles (EVs), such as exosomes, comprising a payload (e.g., an antigen, adjuvant, and / or immunomodulator) and / or a targeting portion. Methods for generating EVs (e.g., exosomes) and methods for using EVs (e.g., exosomes) to treat and / or prevent diseases or conditions, such as cancer, graft-versus-host disease (GvHD), autoimmune diseases, infectious diseases, or fibrotic diseases, are also provided herein.

The present invention relates to interleukin-2 variants, to pharmaceutical compositions comprising said interleukin-2 variants, in a pharmaceutically acceptable carrier, and to their implementation in the prevention or treatment of cancer, or in the prevention or treatment of a disease selected from the group consisting of acute or chronic inflammatory diseases, allergic diseases, autoimmune diseases, graft-versus-host disease and graft rejection.

This invention relates to the use of inhibitors of IL-6 or IL-6R for treating graft-versus-host disease (GVHD) in a subject, including acute GVHD (aGVHD) or chronic GVHD (cGVHD). In particular, this invention relates to methods of treatment of GVHD in a subject in need thereof, wherein the treatment is a first-line treatment of GVHD, the method comprising a combination therapy of (i) administration to the subject of an antibody or fragment which is capable of inhibiting human IL-6 or human IL-6 receptor; and (ii) administration to the subject of a corticosteroid; wherein the administration of the antibody or fragment is given in a first treatment dose within the period 24 hours before or after initiation of the administration of the corticosteroid.

The present invention relates to a method for mass-producing immunosuppressive T cells using human serum albumin. According to the present invention, when peripheral blood stem cells (PBSCs) obtained from individuals administered with granulocyte colony-stimulating factor (G-CSF) are cultured in a medium containing human serum albumin (HSA) or HSA and mercaptoethanol, immunosuppressive T cells having immunosuppressive effects can be mass-produced. It has been confirmed that the immunosuppressive T cells exhibit excellent therapeutic effects against acute graft-versus-host disease. Therefore, the present invention is expected to be useful in the treatment of immune diseases such as acute graft-versus-host disease.

The present invention relates to modified T cells and methods of making and using the same. Specifically, disclosed herein are modified primary human T cells, and populations thereof, comprising a genome in which the CTLA4, PD1, TCRA, TCRB, and / or B2M genes have been edited to produce off-the-shelf universal CAR T cells from allogeneic healthy donors, the off-the-shelf universal CAR T cells can be administered to any patient while reducing or eliminating the risk of immunological rejection or graft versus host disease, and are not susceptible to T cell inhibition; and methods for allogeneic administration of the cells to reduce the likelihood that the cells will trigger a host immune response when the cells are administered to a subject in need thereof.

This invention relates to the field of cell engineering technology, and more particularly to a method for preparing immunomodulatory stem cells for treating graft-versus-host disease (GVHD). The invention provides a method for preparing immunomodulatory stem cells for treating GVHD, comprising the following steps: (1) washing human fat aspirate and digesting it with collagenase to obtain monocytes; (2) inoculating the monocytes obtained in step (1) into differentiation medium and culturing for 2–3 days, then continuing to culture the adherent cells for 18–22 days to obtain mesenchymal stem cells; (3) inoculating the mesenchymal stem cells obtained in step (2) into induction medium for induction culture, and after screening, obtaining immunomodulatory stem cells. The preparation method provided by this invention solves the technical problems of unstable sources, functional decline, and poor therapeutic effects of immunomodulatory stem cells in the prior art, providing a new, efficient, safe, and standardized solution for the treatment of GVHD.

The invention relates to Interleukin-2 (IL-2) variants for the prevention or treatment of immune disorders, including with no limitations allergic, autoimmune, chronic or acute inflammatory and infectious diseases; graft-versus-host disease; graft rejection and cancer. The invention also relates to the use of said IL-2 variants for the screening of anti-IL-2 antibodies with pro-T-effector or pro-T-regulatory cell activity.

Provided are an sgRNA that targets and directs a nuclease to efficiently cleave an HLA-DRA gene, a method for modifying CAR-T cells using the sgRNA, and related gene editing system, agent, and kit. The provided CAR-T cells significantly reduce immunogenicity, which effectively decreases the risks of graft-versus-host disease and immune rejection, and also maintaining the killing activity thereof against tumor cells.

The present disclosure relates generally to the treatment of patients with chronic graft-versus-host disease (cGVHD) following allogeneic hematopoietic stem cell transplantation by administering belumosudil at certain dosages.

This invention discloses 6-substituted 2-([1,1'-biphenyl]-4-yl)quinoline-4-carboxylic acid analogs, which are inhibitors of dihydroorotate dehydrogenase (DHODH) with improved pharmacokinetic properties. The disclosed compounds can be used to treat a variety of disorders and diseases where inhibition of DHODH may be clinically useful, including cancers such as hematologic cancers, including acute myeloid leukemia (AML), graft-versus-host disease, autoimmune disorders, and disorders associated with T-cell proliferation. When administered orally, the disclosed compounds exhibit flipped kinetics, i.e., pharmacokinetics in which the absorption rate, rather than the elimination rate, dominates the pharmacokinetic profile. The disclosed compounds exhibit sustained pharmacokinetic characteristics rather than immediate release characteristics. This summary is intended as a scanning tool for searching in a specific field and is not intended to limit this disclosure.

The present disclosure relates to improved cell compositions and potency assays for obtaining same, which may be suitable for use in connection with T-cell mediated diseases such as graft-versus-host disease (GvHD).